Jubilant Ingrevia Limited has announced the acquisition of 100% stake in Remidex Pharma Private Limited for 165 Million Rupees, marking a strategic expansion into the human nutrition premixes market. The company disclosed this development under Regulation 30 of the SEBI Listing Regulations.

Acquisition Details

The acquisition will be completed through a Share Purchase Agreement, making Remidex a wholly owned subsidiary of Jubilant Ingrevia Limited. The transaction involves cash consideration and is subject to customary closing conditions.

About Remidex Pharma

Remidex Pharma Private Limited, incorporated on June 15, 1981, operates from Bangalore and specializes in manufacturing micronutrient premixes and nutraceuticals. The company also functions as a contract manufacturing organization for leading Indian and multinational pharmaceutical companies.

Financial Performance

Remidex has demonstrated consistent revenue generation over the past three years:

Strategic Rationale

The acquisition aligns with Jubilant Ingrevia's strategy to advance in the value chain towards premixes in the human nutrition space. This move builds upon the company's existing leadership position in Vitamins B3 and B4, expanding its capabilities in the human nutrition industry.

Remidex operates one of the top manufacturing facilities for multivitamin premixes used in nutritional and food products. The Bangalore-based facility holds key certifications including WHO-GMP, FSSC, and FSSAI, ensuring high-grade manufacturing standards.

Market Position

Remidex is recognized as one of the leading players in the human nutrition industry, with strong presence in multivitamin premixes manufacturing and marquee customer base across Indian and multinational pharmaceutical organizations. The company maintains robust innovation and quality control capabilities with comprehensive certifications for pharmaceutical manufacturing.

The acquisition represents a non-related party transaction, with no promoter or group company interest in the target entity. The transaction is expected to strengthen Jubilant Ingrevia's position in the growing human nutrition and pharmaceutical manufacturing sectors.

Jubilant Ingrevia Limited has informed stock exchanges about receiving a GST demand order from tax authorities for Service Tax on Ocean Freight for the financial year 2017-18. The disclosure was made on February 9, 2026, pursuant to Regulation 30 of the SEBI Listing Regulations.

GST Demand Order Details

The Assistant Commissioner, Central Goods & Service Tax, Bijnor has confirmed the demand for Service Tax on Ocean Freight with the following components:

The demand has been raised under Section 73(1) of the Finance Act, 1994 read with Section 142 and Section 174 of the CGST Act, 2017.

Company's Response and Legal Action

Jubilant Ingrevia has indicated it will contest the demand order through proper legal channels. The company plans to file an appeal before the Commissioner (Appeals) against the impugned demand order after receiving the signed or certified copy of the order from the GST authorities.

Financial Impact Assessment

The company has assessed that there will be no material financial or operational impact from this demand order. Management believes it has a strong case to defend on merits and is confident in its legal position regarding the Service Tax demand on Ocean Freight.

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations, specifically under Regulation 30 of the Listing Regulations read with Schedule III and the SEBI Master Circular. The company has also posted the relevant documents on its website at www.jubilantingrevia.com as part of its transparency obligations to stakeholders.